Cumulative incidence of second neoplasms among patients treated for childhood ALL
| Type/site of second malignancies . | Cumulative incidence (95% CI) . | |
|---|---|---|
| Entire cohort . | Patients remaining in initial remission of ALL . | |
| All second malignancies | 10 y: 1.18% (0.8%-1.5%) | 10 y: 0.91% (0.6%-1.2%) |
| 15 y: 2.08% (1.4%-2.8%) | 15 y: 1.48% (0.9%-2.1%) | |
| All solid malignancies | 10 y: 0.82% (0.5%-1.1%) | 10 y: 0.63% (0.3%-0.9%) |
| 15 y: 1.55% (0.9%-2.2%) | 15 y: 1.0% (0.5%-1.5%) | |
| Brain tumors | 10 y: 0.47% (0.2%-0.6%) | 10 y: 0.40% (0.2%-0.6%) |
| 15 y: 0.90% (0.4%-1.4%) | 15 y: 0.61% (0.2%-1.0%) | |
| AML/MDS | 10 y: 0.21% (0.1%-0.3%) | 10 y: 0.14% (0.03%-0.2%) |
| 15 y: 0.27% (0.1%-0.4%) | 15 y: 0.21% (0.03%-0.4%) | |
| NHL | 10 y: 0.08% (0.01%-0.2%) | 10 y: 0.05% (0%-0.1%) |
| 15 y: 0.19% (0.01%-0.4%) | 15 y: 0.18% (0%-0.5%) | |
| Type/site of second malignancies . | Cumulative incidence (95% CI) . | |
|---|---|---|
| Entire cohort . | Patients remaining in initial remission of ALL . | |
| All second malignancies | 10 y: 1.18% (0.8%-1.5%) | 10 y: 0.91% (0.6%-1.2%) |
| 15 y: 2.08% (1.4%-2.8%) | 15 y: 1.48% (0.9%-2.1%) | |
| All solid malignancies | 10 y: 0.82% (0.5%-1.1%) | 10 y: 0.63% (0.3%-0.9%) |
| 15 y: 1.55% (0.9%-2.2%) | 15 y: 1.0% (0.5%-1.5%) | |
| Brain tumors | 10 y: 0.47% (0.2%-0.6%) | 10 y: 0.40% (0.2%-0.6%) |
| 15 y: 0.90% (0.4%-1.4%) | 15 y: 0.61% (0.2%-1.0%) | |
| AML/MDS | 10 y: 0.21% (0.1%-0.3%) | 10 y: 0.14% (0.03%-0.2%) |
| 15 y: 0.27% (0.1%-0.4%) | 15 y: 0.21% (0.03%-0.4%) | |
| NHL | 10 y: 0.08% (0.01%-0.2%) | 10 y: 0.05% (0%-0.1%) |
| 15 y: 0.19% (0.01%-0.4%) | 15 y: 0.18% (0%-0.5%) | |